GRI Bio shares new Phase 2a IPF trial data
GRI Bio, Inc. filed a report noting that it has released additional data from its Phase 2a clinical trial of GRI-0621 in patients with idiopathic pulmonary fibrosis.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
GRI Bio, Inc. filed a report noting that it has released additional data from its Phase 2a clinical trial of GRI-0621 in patients with idiopathic pulmonary fibrosis. The company announced these clinical findings through a press release dated January 28, 2026.
The press release is included as Exhibit 99.1, meaning the detailed trial information and outcomes are provided in that attached document rather than in the body of this report.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did GRI Bio, Inc. (GRI) disclose in this 8-K filing?
GRI Bio disclosed that it issued a press release with additional data from its Phase 2a trial of GRI-0621 in idiopathic pulmonary fibrosis. The detailed information is contained in Exhibit 99.1 attached to the report.
What clinical program is highlighted by GRI Bio, Inc. (GRI) in this filing?
The filing highlights GRI Bio’s Phase 2a clinical trial evaluating GRI-0621 in patients diagnosed with idiopathic pulmonary fibrosis. The company announced additional data from this study in a press release dated January 28, 2026, attached as Exhibit 99.1.
How did GRI Bio, Inc. (GRI) communicate its new clinical data?
GRI Bio communicated the new clinical data through a press release issued on January 28, 2026. That press release, describing additional Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis, is filed as Exhibit 99.1 to the current report.
Which exhibit in the GRI Bio, Inc. (GRI) 8-K contains the trial data details?
Exhibit 99.1 contains the detailed information, as it is the press release issued by GRI Bio on January 28, 2026. The press release presents the additional data from the Phase 2a trial of GRI-0621 in idiopathic pulmonary fibrosis.
Does this GRI Bio, Inc. (GRI) filing include financial statements?
The filing lists only exhibits, including a press release and an inline XBRL cover page data file. It does not present financial statements, focusing instead on additional clinical trial data for GRI-0621 in idiopathic pulmonary fibrosis.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 28, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| of incorporation) | ||||||||||||||
(Address of principal executive offices and zip code)
(619 ) 400-1170
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The Nasdaq Capital Market | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging Growth Company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On January 28, 2026, GRI Bio, Inc. (the “Company”) issued a press release announcing additional data from the Company’s Phase 2a clinical trial investigating GRI-0621 in patients diagnosed with idiopathic pulmonary fibrosis. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release issued by GRI Bio, Inc., dated January 28, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: January 28, 2026 | GRI BIO, INC. | |||||||||||||
| By: | /s/ Leanne Kelly | |||||||||||||
| Name: | Leanne Kelly | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||